bempedoic acid
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hypercholesterolemia
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Trial Timeline
Feb 3, 2017 → Nov 5, 2019
NCT ID
NCT03067441About bempedoic acid
bempedoic acid is a phase 3 stage product being developed by Esperion Therapeutics for Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03067441. Target conditions include Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.
What happened to similar drugs?
20 of 20 similar drugs in Hypercholesterolemia were approved
Approved (20) Terminated (2) Active (0)
✅generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)YuhanApproved
✅colesevelam HCl tablets, and simvastatin tablets + simvastatin tablets and colesevelam HCl placeboDaiichi SankyoApproved
✅colesevelam HCl tablets and fenofibrate tablets + fenofibrate tablets and Welchol placebo tablets + fenofibrate tablets and Welchol placebo tabletsDaiichi SankyoApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05694260 | Phase 2 | Completed |
| NCT03067441 | Phase 3 | Completed |
| NCT02988115 | Phase 3 | Completed |
Competing Products
20 competing products in Hypercholesterolemia